EVOCAIR MDI 125/25 fluticasone propionate 125 microgram/salmeterol (as xinafoate) 25 microgram inhalation

Country: Australia

Bahasa: Inggeris

Sumber: Department of Health (Therapeutic Goods Administration)

Bahan aktif:

salmeterol xinafoate, Quantity: 36.3 microgram/actuation (Equivalent: salmeterol, Qty 25 microgram/actuation); fluticasone propionate, Quantity: 125 microgram/actuation

Boleh didapati daripada:

GlaxoSmithKline Australia Pty Ltd

INN (Nama Antarabangsa):

fluticasone propionate,Salmeterol xinafoate

Borang farmaseutikal:

Inhalation, pressurised

Komposisi:

Excipient Ingredients: norflurane

Laluan pentadbiran:

Inhalation

Unit dalam pakej:

120 doses

Jenis preskripsi:

(S4) Prescription Only Medicine

Tanda-tanda terapeutik:

For the regular treatment of asthma, where the use of a combination product is appropriate. This may include:,*Patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*Patients who are symptomatic on current inhaled corticosteroid therapy.,For the symptomatic treatment of patients with severe COPD (FEV1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. Evocair is not indicated for the initiation of bronchodilator therapy in COPD.

Ringkasan produk:

Visual Identification: Actuator & metal can with concave base fitted with a metering valve. The canister contains a white to off-white suspension. The internal surfaces of the can & the valve are free from obvious defects.; Container Type: Aerosol Can - Metered Dose; Container Material: Al; Container Life Time: 2 Years; Container Temperature: Store below 30 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Status kebenaran:

Registered

Tarikh kebenaran:

2014-05-07